Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Human COVID-19 Immunoglobulin (pH4) for Intravenous Injection (COVID-HIG) in the Treatment of Patients With COVID-19
NCT05173441 is registered in ClinicalTrials.gov with Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase II Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Human COVID-19 Immunoglobulin (pH4) for Intravenous Injection (COVID-HIG) in the Treatment of Patients With COVID-19
- Lead sponsor
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 30, 2021
- Completion date
- November 30, 2023
- Enrollment
- 180 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.